Cytek Biosciences (NASDAQ:CTKB) Receives New Coverage from A

Stephens began coverage on shares of Cytek Biosciences (NASDAQ:CTKB – Free Report) in a research report sent to investors on Thursday, MarketBeat.com reports. The brokerage issued an overweight rating and a $9.00 target price on the stock. A number of other brokerages also recently issued reports on CTKB. Piper Sandler decreased their price target on […]

Related Keywords

Canada , Piper Sandler , Ming Yan , Cytek Biosciences , Royal Bank , Cytek Biosciences Inc , Ameritas Investment Partners Inc , Morgan Stanley , Pricet Rowe Associates Inc , Cytek Biosciences Company Profile , Life Insurance Co , Securities Exchange Commission , Free Report , Moderate Buy , Get Free Report , Exchange Commission , Investment Partners , Cytek Biosciences Daily , Nasdaq Ctkb , Ctkb , Medical , Initiated Coverage , Stephens ,